Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharmaceuticals Share News (FARN)

Share Price Information for Faron Pharmaceuticals (FARN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 97.50
Bid: 95.00
Ask: 100.00
Change: 1.50 (1.56%)
Spread: 5.00 (5.263%)
Open: 96.00
High: 97.50
Low: 96.00
Prev. Close: 96.00
FARN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Renalytix hails trial results; Kingswood buys JFP

Thu, 01st Dec 2022 21:42

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Renalytix PLC - London-based diagnostics company focused on kidney health - Notes the results of primary care use of KidneyIntelX in early-stage chronic kidney disease. Reports a 10% improvement in the HBA1c levels in high-risk patients in first six months. Says that 57% of high-risk patients had action taken within 3-months, compared to 35% for low-risk patients. "The impacts of KidneyIntelX early risk assessment, at 90 days and 180 days, are very encouraging as we can now state that we have observed early intervention in the highest risk patients can result in positive clinical outcomes, before kidney disease advances to a critical point. This prospective study in a real-world health care system setting demonstrates that risk-informed care in the earliest stages of chronic kidney disease is not just a vision, it's a reality," Chief Medical Officer Michael Donovan comments.

----------

Fox Marble Holdings PLC - marble quarrying - Says it was awarded EUR383,177 in damages plus GBP454,584 in costs by in the London Court of International Arbitration from its proceedings against a customer based in India. Says no issues remain to be awarded. The amounts awarded bear an interest rate of 8% per year, it says.

----------

Panther Metals PLC - Canada-focused mineral exploration company - Receives the findings of the follow-up geochemical soil sampling programme 1 in the Barker area of the Manitou Lakes project in Ontario, Canada. Identifies a 300-meter strike extent of linear anomalous and high-grade gold in soils at the Barker prospect area. "These results from the latest round of soil geochemical sampling at Manitou Lakes have almost doubled the strike extent of anomalous gold to 700m at the exciting Barker area prospect in the east of the project area," Chief Executive Darren Hazelwood says.

----------

Kingswood Holdings Ltd - London-based wealth and investment management - Buys Cheshire-based financial advisory firm JFP Holdings Ltd. It is the holding company of JFP Financial Services Ltd. Pays a total cash consideration of up to GBP12.4 million, payable over a two-year period. "The acquisition of JFP Holdings will expand our geographical footprint into the Northwest region and an affluent South Manchester area. JFP Holdings are a high-quality business that has operated with its affiliate Josolyne & Co, a leading chartered accountancy practice, for many years," CEO David Lawrence comments.

----------

Synergia Energy Ltd - Perth-based developer of natural gas assets in India, Indonesia and the UK, formerly called Oilex Ltd - Says that gas production from its C-77H well at the Cambay was around average of 270,000 cubic feet per day in November. Says oil production from the field averaged 23 barrels of oil per day for the month.

----------

Faron Pharmaceuticals Ltd - Turku, Finland-based clinical-stage biopharmaceutical company - Appoints Maija Hollmen as chief scientific officer. "Hollmen is the world-leading expert on Clever-1 biology and Clever-1-expressing tumour-associated macrophages," Chief Medical Officer Marie-Louise Fjallskog says. "Her support is essential to bexmarilimab's development. Faron is pleased to have her on board in the chief scientific officer role to bring her knowledge of the target molecule and develop it further."

----------

Kropz PLC - African phosphate developer - Says that it agreed to a ZAR121.5 million, or USD7.1 million, bridge loan facility to meet its immediate cash requirements at Elandsfontein. Reports that ZAR242.5 million remains available for drawdown over the term of the ZAR550 million equity facility.

----------

Riverstone Credit Opportunities Income PLC - energy infrastructure and energy-transition credit investor - Realised its investment in Hoover CS with a USD1.6 million gross profit. Also reports an upsized investment in a new sustainability-linked first-lien term loan for Hoover. "Hoover CS has a demonstrated track record of helping its customers across multiple end markets improve environmental performance and the circularity of their supply chains, and we are pleased to partner with them on their next phase of growth. This investment is in-line with our stated yield target and focus on sustainability-linked loans. It also means that RCOI is now almost fully invested," Managing Director Danny Flannery comments.

----------

US Solar Fund PLC - owns and operates solar power assets in North America - Reports changes to key personnel at its investment manager New Energy Solar Manager Pty Ltd. Explains that these changes come amid strategic reviews. Says Liam Thomas will continue to lead the strategic review. Says that Adam Haughton will be leaving NESM in December to pursue an alternative career opportunity. "The board remains fully committed to the strategic review process and is entirely focused on delivering a successful outcome that maximises value for all our shareholders as soon as practically possible. The board would like to wish both Liam and Adam well in their new endeavours and thank them for their commitment to USF since its IPO," Chair Gill Nott says.

----------

Gensource Potash Corp - fertilizer development company based in Saskatchewan, Canada - Plans to raise gross proceeds of CAD6.0 million, or GBP3.6 million, in a non-brokered private placement. The offering will consist of up to 20.0 million units of the company at a price of CAD0.15 per unit. Further, it plans to offer up to 15.0 million common shares at a price of CAD0.20 per flow through share. Intends to use the net proceeds from the sale of the units to advance the Tugaske project.

----------

Atome Energy PLC - Leeds, England-based producer and marketer of green hydrogen and ammonia - Says that it achieved "significant" progress at the Villeta project in Paraguay. Says that its green hydrogen and ammonia Villeta project expanded to a world-scale 120 megawatt capacity capable of producing up to 100,000 metric tonnes of ammonia per year. "We are grateful for the confidence that ANDE [the Paraguayan National Power Company] is showing in Atome by increasing our power supply to 120MW, enabling Paraguay to become the leader on the continent in the fast-growing green hydrogen economy. In parallel, we are announcing that, after a competitive tender process including some of the leading engineers in the field, we have appointed as [front-end engineering design] contractor, a very strong consortium of engineering and industrial companies with a track record of delivering ground-breaking energy projects across Latin America and the world, combined with unparalleled expertise in the ammonia sector," CEO Olivier Mussat comments.

----------

By Abby Amoakuh; abbyamoakuh@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
21 Nov 2019 12:56

Faron Pharmaceuticals Applies For Nasdaq First North Growth Listing

Faron Pharmaceuticals Applies For Nasdaq First North Growth Listing

Read more
8 Nov 2019 10:30

UK WINNERS & LOSERS SUMMARY: Games Workshop And Beazley Top FTSE 250

UK WINNERS & LOSERS SUMMARY: Games Workshop And Beazley Top FTSE 250

Read more
7 Nov 2019 17:59

Faron Pharmaceuticals Opens Private Placing To Fund Clevegen Progress

Faron Pharmaceuticals Opens Private Placing To Fund Clevegen Progress

Read more
1 Nov 2019 16:58

LONDON MARKET CLOSE: Upbeat Global Data Promotes Strong End To Week

LONDON MARKET CLOSE: Upbeat Global Data Promotes Strong End To Week

Read more
1 Nov 2019 15:32

Faron Pharmaceuticals Unable To Explain Significant Shares Price Surge

Faron Pharmaceuticals Unable To Explain Significant Shares Price Surge

Read more
9 Oct 2019 14:05

Faron Pharmaceuticals positive on feedback from 'Clevegen' monitoring committee

(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals announced feedback from the 'MATINS' study data monitoring committee on Wednesday, from the ongoing dose escalation study from part 1 of the MATINS trial.

Read more
9 Oct 2019 09:18

Faron Pharmaceuticals To Test New Lower Dose In Clevegen Study

Faron Pharmaceuticals To Test New Lower Dose In Clevegen Study

Read more
2 Oct 2019 14:57

Faron Pharmaceuticals hits bump in road for Traumakine manufacturing

(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals announced on Wednesday that, further to its update in its interim results in relation to the active pharmaceutical ingredient (API) manufacturing process for 'Traumakine', Rentschler Biopharma has sent Faron a letter in which it terminated the agreement concerning the API manufacturing.

Read more
2 Oct 2019 13:13

Manufacturer Ends Traumakine Agreement With Faron Pharmaceuticals

Manufacturer Ends Traumakine Agreement With Faron Pharmaceuticals

Read more
23 Sep 2019 11:37

Faron Pharmaceuticals Ends Traumakine Trial; Loss Narrows On Expenses

(Alliance News) - Faron Pharmaceuticals Oy on Monday said its loss narrowed considerably in the first half of 2019, after it cut back on research & development spending and opted to end a firm

Read more
16 Sep 2019 15:59

UK Earnings, Trading Statements Calendar - Next 7 Days

Tuesday 17 September JTCHalf Year ResultsStafflineHalf Year GroupHalf Year Year

Read more
27 Aug 2019 16:34

Faron Pharma raises ?2.3m to keep it going through the start of 2020

(Sharecast News) - Clinical stage biopharmaceutical company Faron Pharmaceuticals has received valid acceptances and excess applications from qualifying shareholders for a total of 859,513 open offer shares, raising gross proceeds of around €1.01m (£0.92m) at the issue price of 106p per share and at the euro issue price of 119 cents per share, it announced on Tuesday.

Read more
27 Aug 2019 11:38

Faron Pharma Raises EUR2.5 Million; Now Has Working Capital To 2020

(Alliance News) - Faron Pharmaceuticals Oy on Tuesday said it has raised EUR2.5 million via share subscription and open offer.The company raised EUR1.0 million from the issue of 859,513 at

Read more
5 Aug 2019 12:26

Faron Pharmaceuticals To Raise EUR2.1 Million For Clevegen Development

(Alliance News) - Faron Pharmaceuticals Oy on Monday announced a EUR1.1 million subscription and EUR2.0 million open offer to fund the clinical development of cancer drug Clevegen.Shares in

Read more
12 Jul 2019 10:35

WINNERS & LOSERS SUMMARY: Thomas Cook Plunges On Rescue Deal Talks

(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Friday.----------FTSE 100 - WINNERS----------BHP up 1.5%. The -

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.